JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wittmann, M.
Right arrow Articles by Conn, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wittmann, M.
Right arrow Articles by Conn, P. J.

Vol. 302, Issue 2, 433-441, August 2002

Dopamine Modulates the Function of Group II and Group III Metabotropic Glutamate Receptors in the Substantia Nigra Pars Reticulata

Marion Wittmann , Michael J. Marino and P. Jeffrey Conn

Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (M.W., M.J.M., P.J.C.); Department of Neuroscience, Merck Research Laboratories, West Point, Pennsylvania (M.J.M., P.J.C.); and Tierphysiologie, University of Tuebingen, Germany (M.W.)

Recent findings have shown that dendritically released dopamine (DA) plays an important modulatory role in the substantia nigra pars reticulata (SNr). It is therefore possible that the loss of DA observed in Parkinson's disease (PD) could hold important consequences for nigral function. Previously, we have shown that activation of presynaptically localized group II metabotropic glutamate receptors (mGluRs) inhibits excitatory transmission at the subthalamic nucleus (STN)-SNr synapse and that activation of presynaptically localized group III mGluRs decreases excitatory and inhibitory transmission in the SNr. To test the hypothesis that nigral DA can modulate mGluR function in the SNr, we performed whole-cell patch-clamp recordings from gamma -aminobutyric acidergic SNr neurons in slices obtained from rats that were acutely reserpinized. In slices obtained from reserpinized animals, the effect of group II mGluR activation by the selective agonist (+)-2-aminobicyclo[3·1·0]-hexane-2,6-dicarboxylate monohydrate (LY354740) (100 nM), but not group III mGluR activation [L-(+)-2-amino-4-phosphonobutyric acid, L-AP4, 500 µM], at STN-SNr synapses is significantly decreased. This effect could be mimicked in control slices by prior bath application of haloperidol (20 µM) and R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390) (20 µM) but not sulpiride (50 µM). Furthermore, application of dopamine (100 µM) and (±)-6-chloro-7,8-dyhydroxy-3allyl-1-phenyl-2,3,4,5-tetra-hydro-1H-benzazepine (SKF82958) (1 µM) but not quinpirole (10 µM) could rescue the group II mGluR effect in reserpinized slices. The effect of group III mGluR activation (L-AP4, 100 µM) on inhibitory synaptic transmission was also significantly reduced in slices from reserpine-treated animals. This effect was mimicked by haloperidol (20 µM), SCH23390 (20 µM), and sulpiride (50 µM) in control slices. Thus, in a Parkinsonian state, the loss of nigral DA may add to the overall pathophysiological changes in basal ganglia output.


0022-3565/02/3022-0433$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
M. A. Kliem, N. T. Maidment, L. C. Ackerson, S. Chen, Y. Smith, and T. Wichmann
Activation of Nigral and Pallidal Dopamine D1-Like Receptors Modulates Basal Ganglia Outflow in Monkeys
J Neurophysiol, September 1, 2007; 98(3): 1489 - 1500.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. Lopez, N. Turle-Lorenzo, F. Acher, E. De Leonibus, A. Mele, and M. Amalric
Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease
J. Neurosci., June 20, 2007; 27(25): 6701 - 6711.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. C. Vernon, V. Zbarsky, K. P. Datla, D. T. Dexter, and M. J. Croucher
Selective Activation of Group III Metabotropic Glutamate Receptors by L-(+)-2-Amino-4-phosphonobutryic Acid Protects the Nigrostriatal System against 6-Hydroxydopamine Toxicity in Vivo
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 397 - 409.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
K.-Z. Shen and S. W. Johnson
Subthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro
J. Physiol., June 15, 2006; 573(3): 697 - 709.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. P. Tyszkiewicz, Z. Gu, X. Wang, X. Cai, and Z. Yan
Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex
J. Physiol., February 1, 2004; 554(3): 765 - 777.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
O. Valenti, M. J. Marino, M. Wittmann, E. Lis, A. G. DiLella, G. G. Kinney, and P. J. Conn
Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse
J. Neurosci., August 6, 2003; 23(18): 7218 - 7226.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. J. Crocker, P. D. Smith, V. Jackson-Lewis, W. R. Lamba, S. P. Hayley, E. Grimm, S. M. Callaghan, R. S. Slack, E. Melloni, S. Przedborski, et al.
Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease
J. Neurosci., May 15, 2003; 23(10): 4081 - 4091.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.